GigaMune, a South San Francisco, CA-based developer of anti-tumor T Cell receptor programs, secured a strategic convertible debt financing of undisclosed amount.
Investors included several technology and biotech CEOs.
The company will use the proceeds to advance its research program in anti-tumor T cell receptor (TCR) discovery.
Founded in 2017 as a spin-out from GigaGen by Dr. David Johnson, GigaMune is a cancer cell therapy company focused on T cell receptor (TCR) discovery and development. Its patented TCR technologies facilitate discovery of rare TCRs from the immune repertoires of patients with exceptional response to cancer. The company’s research efforts benefit from a strategic partnership with Massachusetts General Hospital and Harvard Medical School.